Company intelligence / Profile preview

Vaderis Therapeutics AG

Ownership: Private
Development stage: Phase 2

Overview

VAD044 received FDA Fast Track Designation for treating Hereditary Hemorrhagic Telangiectasia (HHT) in November 2024. The initial 12-week double-blind part of the trial showed positive results, with continued improvements experienced by patients through 6 months.

Therapeutic areas: Rare Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

engasertib

Beyond the preview

Go deeper on Vaderis Therapeutics AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaderis Therapeutics AG.

Explore the full profile